News

Affordable single-family home construction company LGI Homes (NASDAQ:LGIH) fell short of the market’s revenue expectations in Q1 CY2025, with sales falling 10.1% year on year to $351.4 million. Its GAAP profit of $0.17 per share was 73.1% below analysts’ consensus estimates.

Environmental solutions provider CECO Environmental (NASDAQ:CECO) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 39.9% year on year to $176.7 million. The company’s full-year revenue guidance of $725 million at the midpoint came in 3.5% above analysts’ estimates. Its non-GAAP profit of $0.10 per share was 17.6% above analysts’ consensus estimates.

Environmental solutions provider CECO Environmental (NASDAQ:CECO) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 39.9% year on year to $176.7 million. The company’s full-year revenue guidance of $725 million at the midpoint came in 3.5% above analysts’ estimates. Its non-GAAP profit of $0.10 per share was 17.6% above analysts’ consensus estimates.

Construction equipment company Astec (NASDAQ:ASTE) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, with sales up 6.5% year on year to $329.4 million. Its non-GAAP profit of $0.88 per share was 91.3% above analysts’ consensus estimates.

Alternate site health provider Option Care Health (NASDAQ:OPCH) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 16.3% year on year to $1.33 billion. The company’s full-year revenue guidance of $5.5 billion at the midpoint came in 1.3% above analysts’ estimates. Its non-GAAP profit of $0.40 per share was 19% above analysts’ consensus estimates.

Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported Q1 CY2025 results exceeding the market’s revenue expectations, with sales up 19.5% year on year to $1.05 billion. Its non-GAAP profit of $1.16 per share was 10.6% above analysts’ consensus estimates.

Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported Q1 CY2025 results exceeding the market’s revenue expectations, with sales up 19.5% year on year to $1.05 billion. Its non-GAAP profit of $1.16 per share was 10.6% above analysts’ consensus estimates.